Abstract
To evaluate the pregnancy and neonatal outcome after ovulation induction with aromatase inhibitor letorozole or clomiphene citrate (CC). A prospective, randomized study. The study included couples directed for IVF/ICSI treatment to the IVF unit at Kyono ART clinic, Japan, from May, 1995 to December, 2010. The couples, who all gave written, informed consent to undergo this method, were divided into two groups. (letorozole and CC). Letorozole at a dose of 5 mg/day or CC at a dose of 100mg/day was given to patients on days 3-7 of menstrual cycles. Patients were treated with hMG or FSH or a combination of the two each day, starting from day 8. GnRH antagonist (Cetrotide 0.25mg/day) was administered when the dominant follicle reached 14 mm in diameter. Ovulation was triggered with urinary hCG. We compared the result of assisted reproductive technology (ART) and neonatal conditions with letorozole and with CC. The clinical pregnancy rate was significantly higher in the letorozole group in comparison to the CC group. There were no differences in the results of other ART and neonatal outcomes between the two groups (Table 1). Aromatase inhibitors and CC resulted in favorable pregnancy and neonatal outcomes, and indicated that children were growing normally. It is shown that the two medicines are safe for mothers and fetuses.Tabled 1Table1letorozoleCCNo. of oocyte pick up cycles821912Maturation rate (%)77.7 (3225/4152)81.4 (2067/2538)NSFertilization rate (%)68.7 (2217/3225)71.4 (1476/2067)NSBlastocyst formation rate (%)42.3 ( 566/1339)42.9 ( 313/ 699)NSClinical pregnancy rate (%)/embryo transfer22.3 (207/ 929)15.5 ( 113/ 731)P=0.0005No. of ongoing pregnancies (n)3835Abortion rate (%)32.9 (68/207)31.9 (36/113)NSNo. of births (n)single:95 twin:5single:39 twin:3Average birth weight (g)single:2910 ± 435 twin:1929 ± 299single:3017 ± 458 twin:1941 ± 178NSDeformed child (n)1∗trisomy 21 (Down syndrome)0∗ trisomy 21 (Down syndrome) Open table in a new tab
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
